A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment

Phase 1 Completed 33 enrolled Amgen

Non-randomizedParallel-groupOpen-labelBasic science

Summary

The primary objective of this study is to evaluate the pharmacokinetics (PK) of a single dose of olpasiran in participants with normal renal function and participants with various degrees of renal impairment.

Timeline

Start: 2022-09-13
Primary completion: 2023-10-24
Completion: 2023-12-19

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Olpasiran	Unknown	—	Subcutaneous

A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment

Summary

Timeline

Drugs

Indications